DrugPatentWatch Database Preview
Drugs in Development Information for Delamanid
» See Plans and Pricing
What is the drug development status for Delamanid?
Delamanid is an investigational drug.
There have been 18 clinical trials for Delamanid.
The most recent clinical trial was a Phase 2 trial, which was initiated on March 1st 2003.
The most common disease conditions in clinical trials are Tuberculosis, Tuberculosis, Multidrug-Resistant, and Tuberculosis, Pulmonary. The leading clinical trial sponsors are Otsuka Pharmaceutical Development & Commercialization, Inc., National Institute of Allergy and Infectious Diseases (NIAID), and Partners in Health.
Summary for Delamanid
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 25 |
| WIPO Patent Applications | 159 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2003-03-01) |
| Vendors | 38 |
Recent Clinical Trials for Delamanid
| Title | Sponsor | Phase |
|---|---|---|
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) | Ludwig-Maximilians - University of Munich | Phase 2 |
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) | Radboud University | Phase 2 |
| PanACEA DElpazolid Dose-finding and COmbination DEvelopment (DECODE) | University of California, San Francisco | Phase 2 |
Clinical Trial Summary for Delamanid
Top disease conditions for Delamanid
Top clinical trial sponsors for Delamanid
US Patents for Delamanid
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
